On the occasion of World Breast Cancer Day, 19 October, Sabadell Protection wished to make a €10,000 donation in the fight against breast cancer to the Spanish Association Against Cancer. Specifically, in the research project ‘Identification of new weak points to overcome resistance in metastatic breast cancer’ by Dr Fara Brasó Maristany, which will contribute to improving the treatment and survival of patients with hormonal breast cancer.
To commemorate this day, Clara Armengol, Sustainability Director of Sabadell Seguros and Dr Fara Brasó, doctor and researcher at the Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), have participated in this video explaining the progress of the project and raising awareness of the need to invest in cancer research:
Collaboration with the Association Against Cancer has become a key pillar for Sabadell Protection. As part of its ‘insurance with a cause’ initiative, which strives to link its products to social and environmental causes, and thanks to its Life Care life insurance, designed to cover its customers in the event of serious illness, it has already donated more than €230,000 in recent years to support scientific research and cancer centres and associations. This is just one example of their present and future commitment to society.
Thanks to this project, it has been possible to discover why some patients with hormone receptor-positive and HER2-negative metastatic breast cancer do not respond well to CDK inhibitor treatments. As a result, new therapeutic strategies, such as FGFR4 blockade, have been identified that could be effective for patients who do not improve with CDK4/6 inhibitors. Furthermore, a biomarker has been developed to help determine which patients with metastatic breast cancer will benefit most from CDK4/6 inhibitors and which may need other, more appropriate treatments to tackle their disease.
Ultimately, funding and support for projects like this will make it possible to make progress in the understanding of metastatic breast cancer, to offer personalised treatments for each patient facing this disease, and to continue to improve both quality of life and survival rates.
